Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

K Linton; A Gibb; M Ranson; A Greystoke; T Illidge; E Smith; A Pettit; A Lister; C Dive; P Johnson; J Radford

Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

K Linton, A Gibb, M Ranson, A Greystoke, T Illidge, E Smith, A Pettit, A Lister, C Dive, P Johnson, J Radford

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - Jun 2011
Event	11th International Conference on Malignant Lymphoma - Lugano, Switzerland Duration: 1 Jan 1824 → …

Conference

Conference	11th International Conference on Malignant Lymphoma
City	Lugano, Switzerland
Period	1/01/24 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Linton, K., Gibb, A., Ranson, M., Greystoke, A., Illidge, T., Smith, E., Pettit, A., Lister, A., Dive, C., Johnson, P., & Radford, J. (2011). Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. Poster session presented at 11th International Conference on Malignant Lymphoma, Lugano, Switzerland.

@conference{f82e3889ca704df39820ddbbe1da453c,

title = "Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity",

author = "K Linton and A Gibb and M Ranson and A Greystoke and T Illidge and E Smith and A Pettit and A Lister and C Dive and P Johnson and J Radford",

year = "2011",

month = jun,

language = "English",

note = "11th International Conference on Malignant Lymphoma ; Conference date: 01-01-1824",

}

Linton, K, Gibb, A, Ranson, M, Greystoke, A, Illidge, T, Smith, E, Pettit, A, Lister, A, Dive, C, Johnson, P & Radford, J 2011, 'Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity', 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 1/01/24.

Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. / Linton, K; Gibb, A; Ranson, M et al.
2011. Poster session presented at 11th International Conference on Malignant Lymphoma, Lugano, Switzerland.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

AU - Linton, K

AU - Gibb, A

AU - Ranson, M

AU - Greystoke, A

AU - Illidge, T

AU - Smith, E

AU - Pettit, A

AU - Lister, A

AU - Dive, C

AU - Johnson, P

AU - Radford, J

PY - 2011/6

Y1 - 2011/6

M3 - Poster

T2 - 11th International Conference on Malignant Lymphoma

Y2 - 1 January 1824

ER -

Linton K, Gibb A, Ranson M, Greystoke A, Illidge T, Smith E et al.. Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. 2011. Poster session presented at 11th International Conference on Malignant Lymphoma, Lugano, Switzerland.